stockrow
Friday 6 November 2026
Export SEPN’s income statement to Excel — free account
Septerna, Inc.
SEPN Healthcare Biotechnology
Septerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, up 4,174.5% from fiscal 2024.
- Revenue
- +22,375.6%
- EPS
- +48.2%
- Free cash flow
- −9.01%
Quarter to June 2026, against a year earlier
49.54
2.19
+4.63%
Follow SEPN
Alert me
Septerna, Inc. (SEPN) Return on assets
Septerna, Inc.'s return on assets over the twelve months to 30 June 2026 was −4.94%, up 4.4 percentage points from fiscal 2025 (−9.29%). That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −9.29% | 15.16 |
| FY2024 | −24.5% | (24.45) |
| FY2023 | 0.00% | — |
Return on assets against peers
| Company | Return on assets |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | 46.5% |
| VCEL Vericel Corporation compare | 6.86% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.00% |
| SEPN Septerna, Inc. | −4.94% |
| ZYME Zymeworks Inc. compare | −37.3% |
| PVLA Palvella Therapeutics, Inc. compare | −37.7% |
| IMNM Immunome, Inc. compare | −59.0% |
| VERA Vera Therapeutics, Inc. compare | −72.3% |
| BHVN Biohaven Ltd. compare | −161.3% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on SEPN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- The full statement